The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection
Study Details
Study Description
Brief Summary
Pathogen-free, concentrated, pooled convalescent plasma has higher SARS-CoV2 antibody titers and neutralizing antibody activities, without requiring blood group compatibility that allows patient accessibility in a shorter time and has safe plasma characteristic.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
The efficacy of SARS-CoV2 standard single donor convalescent plasma varied according to the application time and most importantly the amount of antibody that is administered. Single donor plasma has some drawbacks; such as the insufficient levels of neutralizing antibody activities, the requirements of blood group compatibility, and the risk of infection transmission. In this study, the efficacy and safety of pathogen inactivated, isohemagglutinin-depleted (concentrated) and pooled convalescent plasma was investigated.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Single donor convalescent plasma Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with single donor plasma |
|
ACB- IP 1.0 Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with ACB- IP 1.0 pathogen-free concentrated cocktail convalescent plasma |
Outcome Measures
Primary Outcome Measures
- Mortality Rate [6 Months]
A mortality rate is a measure of the frequency of occurrence of death in a defined population during a specified interval.
- Length of Hospitalization [6 Months]
The average length of stay in hospitals (ALOS) is often used as an indicator of efficiency
Secondary Outcome Measures
- Side Effects [6 Months]
Problems that occur when treatment goes beyond the desired effect. Or problems that occur in addition to the desired therapeutic effect.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Are over the age of 60 or-
-
Between the ages of 18-60, serious comorbidities (cancer, COPD, cardiovascular illness, hypertension, DM)
-
Clinically diagnose COVID-19 or radiological diagnosed COVID-19 pnemonia
Exclusion Criteria:
- Multiple Organ Failure
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Acıbadem Labcell Cellular Therapy Laboratories | Istanbul | Turkey | 34758 | |
2 | Acibadem Altunizade Hospital | Istanbul | Turkey |
Sponsors and Collaborators
- Acibadem University
- Acıbadem Labcell
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Acibadem Healthcare Group